ArriVent Biopharma presents Phase 1 data for ARR-217 in advanced solid tumors
AVBP•ArriVent Biopharma reported preliminary ARR-217 results in colorectal cancer: a 44.8% response rate among 29 patients at 6 mg/kg, with grade 3 or higher treatment-related adverse events in 20.4%. Its 480-patient Phase 3 firmonertinib trial is ongoing.
1. ARR-217 results
In Phase 1b colorectal cancer dose optimization, preliminary results at 6 mg/kg showed a 44.8% response rate among 29 patients. Grade 3 or higher treatment-related adverse events occurred in 20.4% of patients at that dose, and no patients discontinued treatment.
2. Firmonertinib trial
ArriVent Biopharma continues enrolling its 480-patient global Phase 3 trial of firmonertinib for first-line EGFR PACC-mutated non-small cell lung cancer. The trial compares 240 mg daily with investigators’ choice of osimertinib or afatinib. Earlier first-line PACC data showed a 68.2% confirmed response rate at 240 mg and median progression-free survival of 16 months.
